AVPdb

AVPdb catalogs experimentally verified antiviral peptides and associated experimental annotations and computed peptide properties to support antiviral research.

Key Features:

• Peptide collection: Contains 2,683 experimentally verified peptides, including 624 chemically modified variants.
• Virus coverage: Targets over 60 viruses, including Influenza, Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Respiratory Syncytial Virus (RSV), Hepatitis B Virus (HBV), Dengue Virus (DENV), and Severe Acute Respiratory Syndrome Coronavirus (SARS).
• Experimental annotations: Provides peptide sequence, length, source, virus targeted, virus family, cell line used, efficacy measures, target step/protein, assay used, and PubMed references.
• Physicochemical and structural data: Includes calculated physicochemical properties and predicted peptide structures.
• Analysis tools: Offers various analysis tools for computational exploration of peptide sequences and properties.
• Clinical relevance: Documents many synthetic peptide-based drugs currently undergoing clinical trials.
• HIV peptides: HIV-targeting peptides are maintained separately in HIPdb.

Scientific Applications:

• Antiviral discovery and optimization: Supports identification and optimization of peptide candidates for antiviral therapeutics, including evaluation of modified variants for efficacy and stability.
• Mechanistic studies: Enables investigation of peptide inhibition targets, specific viral proteins, and viral life-cycle steps affected by peptides.
• Comparative analyses: Facilitates comparison of peptide activity and properties across viruses and virus families.
• Literature-linked validation: Serves as a source of experimentally validated data with PubMed references for verification and follow-up studies.

Methodology:

Prediction of peptide structures and computation of physicochemical properties, together with provision of analysis tools for data exploration.